Beacon Hospital

Cancer Clinical Research Center

Join the fight against disease and contribute to medical progress by participating in a clinical research trial at Beacon Hospital.

Beacon Hospital

Cancer Clinical Research Center

Join the fight against disease and contribute to medical progress by participating in a clinical research trial at Beacon Hospital.

Overview

Clinical research studies are vital components of the evidence-based research approach of Beacon Hospital’s Clinical Research Centre.

We offer new treatments in cancer patients, such as new medications, new treatment combinations, new approaches (surgery or radiation therapy), or new methods (gene therapy). This research aims to find better ways to treat cancer and help cancer patients.

beacon-advance-package-male-health-screening-beacon-hospital-malaysia

What are the benefits for the participants?

We’ll cover most of the treatment costs. Participants get up-to-date care from cancer experts and receive either a new treatment being tested or the best available standard treatment for their cancer. Individuals who participate may be helped personally by the treatment(s) they receive.

If a new treatment proves effective in a study, it may become a new standard treatment that can help many patients. Most of today’s most effective standard treatments are based on previous study results, such as those for breast, colon, rectal, and childhood cancers.

Is the research safe & will there be any guarantee?

While research studies are essential in therapeutic advancement, Beacon Hospital’s Clinical Research Centre prioritizes patients’ rights, safety, and well-being of the patients. Apart from the fact that all our clinical studies have secured approval from the Medical and Research Ethics Committee of the Ministry of Health, Malaysia, we also comply with local and international Good Clinical Practice (GCP) standards to safeguard the ethical interests of patients.

There are no guarantees that a new treatment being tested will not carry risks or produce good results. Participants may be among the first to benefit if a new treatment proves effective or more effective than the standard treatment.

Any positive results from the programs?

Our oncology team has participated in numerous types of research, including comparing the effectiveness of different chemotherapy treatments; resistance to inhibitors; epigenetic changes in nasopharyngeal cancer; and treatment for advanced or metastatic gastroesophageal junction adenocarcinoma, among others.

How to join?

Fill in the form below & our Medical Enquiry will contact you.

beacon-advance-package-male-health-screening-beacon-hospital-malaysia
beacon-advance-package-male-health-screening-beacon-hospital-malaysia

What are the benefits for the participants?

We’ll cover most of the treatment costs. Participants get up-to-date care from cancer experts and receive either a new treatment being tested or the best available standard treatment for their cancer. Individuals who participate may be helped personally by the treatment(s) they receive.

If a new treatment proves effective in a study, it may become a new standard treatment that can help many patients. Most of today’s most effective standard treatments are based on previous study results, such as those for breast, colon, rectal, and childhood cancers.

Is the research safe & will there be any guarantee?

While research studies are essential in therapeutic advancement, Beacon Hospital’s Clinical Research Centre prioritizes patients’ rights, safety, and well-being of the patients. Apart from the fact that all our clinical studies have secured approval from the Medical and Research Ethics Committee of the Ministry of Health, Malaysia, we also comply with local and international Good Clinical Practice (GCP) standards to safeguard the ethical interests of trial patients.

There are no guarantees that a new treatment being tested will not carry risks or produce good results. Participants will be among the first to benefit if a new treatment proves effective or more effective than the standard treatment.

Any positive results from the programs?

Our oncology team has participated in numerous types of research, including comparing the effectiveness of different chemotherapy treatments; resistance to inhibitors; epigenetic changes in nasopharyngeal cancer; and treatment for advanced or metastatic gastroesophageal junction adenocarcinoma, among others.

beacon-advance-package-male-health-screening-beacon-hospital-malaysia

How to join?

Fill in the form below & our Medical Enquiry will contact you.

Your participation could make a life-changing impact on yourself and others!

Join us to fight cancer

We’re actively doing Clinical Research Programs for lung, breast & Colon cancer.

Your participation could make a life-changing impact on yourself and others!

Lung Cancer

KontRASt-02

Study of JDQ443 in participants with locally advanced or Metastatic KRAS G12C Mutant non-small cell lung cancer

PALOMA3

A phase 3, open-label, randomized study of Lazertinib with subcutaneous Amivantamab administered via manual injection compared with intravenous Amivantamab or Amivantamab subcutaneous on body delivery system in patients with EGFR-mutated advanced or Metastatic non-small cell lung cancer after progression on osimertinib and Chemotherapy.

PALOMA 2

A phase 2, open-label, parallel cohort study of subcutaneous Amivantamab in multiple regimens in patients with advanced or metastatic solid tumors, including EGFR-mutated non-small cell lung cancer.

InCyte Podium (INCMGA0012-304)

A Randomized, Double-Blind, Phase 3 Study of Platinum-based Chemotherapy with or without INCMGA00012 in First-Line Metastatic Squamous and Nonsquamous Non-Small Cell Lung Cancer Participants (POD1UM 304)

MARIPOSA2

A phase 3, Open-Label, Randomised Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Advanced or Metastatic NSCLC After Osimertinib Failure.

Pacific 8

A Phase 3, Randomised, Double-blind, Placebo-controlled, Multicentre, International Study of Durvalumab plus Domvanalimab (AB154) in Participants with Locally Advanced (Stage III), Unresectable Non small Cell Lung Cancer Whose Disease has not Progressed Following Definitive Platinum based Concurrent Chemoradiation Therapy

Adaura 2

A Phase III, Double-blind, Randomised, Placebo-Controlled, International Study to assess the Efficacy and Safety of Adjuvant Osimertinib versus Placebo in Participants with EGFR mutation-positive Stage IA2-IA3 Non-small Cell Lung Cancer, following Complete Tumour Resection

Lung Cancer

KontRASt-02

Study of JDQ443 in participants with locally advanced or Metastatic KRAS G12C Mutant non-small cell lung cancer

PALOMA3

A phase 3, open-label, randomized study of Lazertinib with subcutaneous Amivantamab administered via manual injection compared with intravenous Amivantamab or Amivantamab subcutaneous on body delivery system in patients with EGFR-mutated advanced or Metastatic non-small cell lung cancer after progression on osimertinib and Chemotherapy.

PALOMA 2

A phase 2, open-label, parallel cohort study of subcutaneous Amivantamab in multiple regimens in patients with advanced or metastatic solid tumors, including EGFR-mutated non-small cell lung cancer.

InCyte Podium (INCMGA0012-304)

A Randomized, Double-Blind, Phase 3 Study of Platinum-based Chemotherapy with or without INCMGA00012 in First-Line Metastatic Squamous and Nonsquamous Non-Small Cell Lung Cancer Participants (POD1UM 304)

MARIPOSA2

A phase 3, Open-Label, Randomised Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Advanced or Metastatic NSCLC After Osimertinib Failure.

Pacific 8

A Phase 3, Randomised, Double-blind, Placebo-controlled, Multicentre, International Study of Durvalumab plus Domvanalimab (AB154) in Participants with Locally Advanced (Stage III), Unresectable Non small Cell Lung Cancer Whose Disease has not Progressed Following Definitive Platinum based Concurrent Chemoradiation Therapy

Adaura 2

A Phase III, Double-blind, Randomised, Placebo-Controlled, International Study to assess the Efficacy and Safety of Adjuvant Osimertinib versus Placebo in Participants with EGFR mutation-positive Stage IA2-IA3 Non-small Cell Lung Cancer, following Complete Tumour Resection

Breast Cancer

Colorectal Cancer

Lidera

A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician’s Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer

Krystal 10

Phase 3 Study of MRTX849 in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation

Origami -1

A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer

Breast Cancer

Lidera

A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician’s Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer

Colorectal Cancer

Krystal 10

Phase 3 Study of MRTX849 With in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation

Origami -1

A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer

Contact us for more information!

Join the fight against the disease!

Submit your contact details at the form below